13. 11. 2025
Krka Reports January to September 2025 Business Results
3 min. read
From January to September 2025, the Krka Group generated revenue of €1,534 million, up 7% year on year, yielding €323.7 million net profit, a 15% year-on-year increase. The Krka Supervisory Board deliberated on the January to September 2025 interim report for the Krka Group and Krka, d. d., Novo mesto at its regular meeting yesterday.
President of the Management Board and Chief Executive Jože Colarič explained: ‘The Krka Group continued to record good business results also in the third quarter. We increased our product and service sales by 7% in the first nine months, generating over €1.5 billion. Sales grew across five sales regions, most of our markets, and all product and service groups. We added 17 new products to our product portfolio. Net profit increased by 15% year on year. Based on achieved results, we expect the Krka Group target sales to outstrip the plans and create €2,020 million in product and service sales, and net profit of €383 million.
We presented the updated 2026–2030 Krka Group Development Strategy to the Supervisory Board yesterday. The strategy prioritises uninterrupted supply of medicines and further growth in individual markets and selected therapeutic categories, primarily for treating chronic diseases.
We plan to strengthen and optimise our vertically integrated business model, proven to be an effective strategic guideline and our competitive advantage, as it ensures high standards of product quality, safety, and efficacy. We intend to maintain our focus on maximising the long-term profitability of the products sold. Our strategy aims to deliver on sustainability goals and business targets, reinforcing our commitment to maintaining our economic, social, and environmental responsibility to the environment in which we operate. The revised strategy serves as the underlying structure for the 2026 business plan. We plan product and service sales at €2,132 million and net profit at €405 million.’
Financial highlights
| € thousand | Index | ||
| Revenue | 1,534,028 | 1,434,662 | 107 |
| – Of that revenue from contracts with customers (products and services) | 1,529,127 | 1,427,514 | 107 |
| Gross profit | 884,852 | 819,323 | 108 |
| Earnings before interest, tax, depreciation and amortisation (EBITDA) | 436,734 | 401,748 | 109 |
| Operating profit (EBIT) | 367,154 | 332,609 | 110 |
| Profit before tax (EBT) | 395,453 | 337,331 | 117 |
| Net profit | 323,654 | 281,027 | 115 |
| R&D expenses | 143,733 | 136,364 | 105 |
| Investments | 66,742 | 91,703 | 73 |
Performance ratios
| Gross profit margin | 57.7% | 57.1% |
| EBITDA margin | 28.5% | 28.0% |
| EBIT margin | 23.9% | 23.2% |
| EBT margin | 25.8% | 23.5% |
| Net profit margin (ROS) | 21.1% | 19.6% |
| Return on equity (ROE) | 19.0% | 17.1% |
| Return on assets (ROA) | 14.8% | 13.4% |
| Liabilities/Equity | 0.287 | 0.278 |
| R&D expenses/Revenue | 9.4% | 9.5% |
Sales
Estimated Product and Service Sales by Region
Region Slovenia,6.5
Region South-East Europe,14.3
Region East Europe,34.9
Region Central Europe,22.9
Region West Europe,17.8
Region Overseas Markets,3.6